138 related articles for article (PubMed ID: 29474179)
1. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
Mizukami A; Kaise T; Van Kriekinge G
Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
[TBL] [Abstract][Full Text] [Related]
2. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
3. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
4. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
5. Health and economic burden of HPV-related diseases in Singapore.
Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
[TBL] [Abstract][Full Text] [Related]
6. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
Herse F; Reissell E
Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
[TBL] [Abstract][Full Text] [Related]
7. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
9. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: accounting for CIN1 and genital warts in addition to CIN2/3 and cervical cancer.
Shavit O; Raz R; Stein M; Chodick G; Schejter E; Ben-David Y; Cohen R; Arbel D; Shalev V
Appl Health Econ Health Policy; 2012 Mar; 10(2):87-97. PubMed ID: 22201263
[TBL] [Abstract][Full Text] [Related]
11. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries.
Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Khorprasert C; Taneepanichskul S
Value Health; 2012; 15(1 Suppl):S29-34. PubMed ID: 22265063
[TBL] [Abstract][Full Text] [Related]
12. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
Dasbach EJ; Insinga RP; Elbasha EH
BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
14. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
15. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
17. The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands.
van Ballegooijen M; Koopmanschap MA; Habbema JD
Eur J Cancer; 1995 Sep; 31A(10):1672-6. PubMed ID: 7488423
[TBL] [Abstract][Full Text] [Related]
18. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Brisson M; Van de Velde N; De Wals P; Boily MC
Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
[TBL] [Abstract][Full Text] [Related]
19. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.
Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V
Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028
[TBL] [Abstract][Full Text] [Related]
20. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.
Salo H; Leino T; Kilpi T; Auranen K; Tiihonen P; Lehtinen M; Vänskä S; Linna M; Nieminen P
Int J Cancer; 2013 Sep; 133(6):1459-69. PubMed ID: 23463194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]